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Abstract: Diabetes mellitus is associated with well-known increases in cardiovascular morbidity and mortality. In diabet-
ics with stable coronary artery disease, the best therapeutic option is widely discussed. Current studies comparing surgical 
to percutaneous revascularization have been unable to definitely demonstrate any significant advantage of one strategy 
over the other regarding the prevention of cardiac death or acute myocardial infarction. Therefore, even taking into ac-
count clinical and angiographic information as well as the risks determined by each type of treatment, the decision regard-
ing the best therapeutic strategy in diabetics with stable coronary artery disease is still complex. 
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INTRODUCTION 
  According to data from the WHO, from 1995 to 2005 the 
world´s adult population will increase 64%, while the num-
ber of diabetic patients will increase 122%. In developed 
countries, the number of adults with diabetes mellitus (DM) 
will increase 42%, while in developing countries the increase 
will be of 170% [1]. In general terms, it is estimated that the 
prevalence of DM will increase from 2.8% in 2000 to 4.4% 
in 2030 [2]. These data underscore the importance of preven-
tion, treatment and control of the disease, especially if we 
take into account the 2 to 4 times higher cardiovascular mor-
tality found in these individuals [1-4] and the 65% of cardio-
vascular deaths in diabetics, most of these related to coronary 
artery disease (CAD) [5]. 
RELATIONSHIP BETWEEN DIABETES AND 
CORONARY ARTERY DISEASE AND ITS IMPLICA-
TIONS ON THE  TREATMENT FOR CORONARY 
ARTERY DISEASE 
  DM has been associated with accelerated atherosclerosis 
due to a number of factors, such as endothelial dysfunction 
[6], decreased coronary flow reserve [7], increased platelet 
activity [8-10], increased levels of fibrinogen and factor VII 
[11], decreased fibrinolytic activity and of antithrombin III 
[11] and increased levels of plasminogen activator inhibitor 1 
[12]. Morphologic characterization of the coronary arteries 
of diabetic patients who died suddenly has found a greater 
burden of atherosclerotic plaque, increased lipid cores, as 
well as increased macrophage and T-lymphocyte infiltration 
when compared to non-diabetics with sudden death
 [13].  
  In asymptomatic diabetics, significant coronary artery 
obstructions have been found in over 75% of the patients, 
and multivessel involvement in over 50% [13,14]. Moreover,  
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DM is associated with a higher prevalence of left main coro-
nary artery disease but less collateral circulation [15,16]. 
Coronary lesions in diabetics are generally more calcified 
than in nondiabetics [16], and compensatory arterial remod-
elling is often inadequate [17].  
  All of the former contribute to the peculiar angiographic 
aspects of DM (diffuse and often distal atherosclerotic in-
volvement of coronary arteries), to the increased risk of ad-
verse coronary events and of incomplete coronary revascu-
larization, either surgical or percutaneous [18-22]. The pres-
ence of diabetic nephropathy identifies a subgroup of pa-
tients with reduced survival after coronary artery bypass 
[23]. Moreover, after bypass surgery, vascular grafts (espe-
cially venous) occlude more frequently in diabetics than in 
non-diabetics [24,25].  
  In patients undergoing baloon percutaneous coronary 
intervention (PCI), restenosis is more frequent among diabet-
ics, and that also has an impact on long-term survival [26-
28]. Coronary stents also have an increased incidence of 
restenosis, especially in insulin-dependent diabetics; this is 
also related to higher rates of death, acute myocardial infarc-
tion (AMI) and the need for repeated revascularization in 
diabetic patients, compared to non-diabetics [29]. In addi-
tion, although pharmacologic stents have reduced restenosis 
and the need for repeat revascularization when compared to 
bare-metal stents, the incidence of restenosis and repeat 
revascularization have also been consistently higher in dia-
betics compared to non-diabetics [30-32]. Diabetes mellitus 
is an independent risk factor for major cardiovascular events 
after PCI [33] and for pharmacologic stent thrombosis 
[34,35].  
  Therefore, DM is associated with an increased risk of 
adverse events no matter which type of myocardial revascu-
larization is chosen, either surgical or percutaneous. The 
question that follows is if there is any benefit of myocardial 
revascularization over medical treatment in diabetics with 
stable CAD. 334    Current Cardiology Reviews, 2010, Vol. 6, No. 4  Lorenzo et al. 
 
  Regarding that question, a retrospective analysis of dia-
betic patients included in the MASS II study has demon-
strated that myocardial revascularization, compared to medi-
cal treatment, reduced the risk of death between the first and 
fifth years of follow-up. However, considering the whole 
follow-up, from randomization to five years, there was no 
difference among the 3 treatment groups [36]. Sorajja et al, 
in an observational study in which asymptomatic diabetics 
were followed for 5 years and stratified into low, intermedi-
ate or high risk according to stress myocardial perfusion 
SPECT, have found that surgical revascularization, when 
compared to medical treatment, was only favored in high-
risk patients [37].  
  BARI 2D is the only study which has compared medical 
treatment to myocardial revascularization in diabetics [38]. 
This study included 2,368 diabetic patients with stable CAD, 
either symptomatic or not, who were randomized to intensive 
medical treatment or to intensive medical treatment plus 
percutaneous or surgical revascularization. The study dem-
onstrated that there were no significant differences among 
treatment strategies regarding mortality or the incidence of 
major adverse cardiovascular events [38]. However, revascu-
larization significantly reduced major adverse cardiovascular 
events among patients selected for a strategy of surgical 
revascularization, but that was not true for patients selected 
for percutaneous revascularization. That difference was de-
termined by a higher incidence of nonfatal acute myocardial 
infarction in medically treated patients [38]. 
  One interesting aspect of this study was that the type of 
revascularization (surgical or percutaneous) was left at the 
discretion of the study´s investigators, in a way that the 
choice of bypass surgery or PCI was based on angiographic 
criteria such as the location and extent of coronary lesions, as 
well as clinical and demographic variables [39]. Therefore, 
most patients undergoing bypass had higher angiographic 
severity (more 3-vessel disease, more 70% lesions, more 
proximal lesions of the left anterior descending artery, as 
well as type C lesions), were older, with more previous coro-
nary interventions [39]. It was not surprising, then, that pa-
tients treated with PCI had similar prognosis to those medi-
cally treated, since they had less extensive and severe CAD, 
as well as normal LV function [40]. Finally, that study was 
not designed and therefore was not powered either to com-
pare revascularization strategies or to compare PCI or sur-
gery to medical treatment, and regarding superiority of one 
of the treatment strategies it should be considered hypothe-
sis-generating. 
TAKING ALL THIS INTO CONSIDERATION, 
WHICH IS THE BEST REVASCULARIZATION 
STRATEGY FOR DIABETIC PATIENTS WITH STA-
BLE CAD AND NORMAL LV FUNCTION? 
  Theoretically, coronary artery bypass grafting surgery 
(CABG) is advantageous since grafts bypass the proximal 
2/3 of the coronary arteries, where most plaque ruptures 
occur, generating clinical events, while PCI offers target-
lesion treatment, leaving other plaques unprotected [41]. In 
addition, CABG also provides complete revascularization 
more often than PCI, what may lead to less repeat revascu-
larization procedures and less angina during follow-up [42]. 
On the other side, CABG may have complications, and even 
those considered mild and reversible may prolong hospitali-
zation [43,44]; the short-term risk of cerebrovascular acci-
dents (CVA) is also increased [45].  
  The Bypass Angioplasty Revascularization Investigation 
Study (BARI) has demonstrated that in 10 years of follow-up 
diabetics patients had the highest benefit with CABG (57.9% 
of survival) compared to baloon PCI (45.5%). However, that 
was true only for patients who received internal mammary 
grafts in the LAD artery [46]. Other two randomized trial, 
ARTS [47] and SoS [48], in which bare metal stents were 
used, have shown similar results, that is, that diabetic pa-
tients who underwent CABG had lower 5-year mortality than 
those who had PCI. In the ARTS study, 5-year mortality in 
diabetics was 13.4% for those who underwent PCI and 8.3% 
for those who had CABG, while in SoS the 6-year mortality 
was 17.6% for PCI and 5.4% for CABG. Also, in a substudy 
of 452 patients from the SYNTAX study, CABG determined 
a lower incidence of composite endpoints (death, AMI, CVA 
or repeat revascularization) compared to PCI, but there was 
no difference regarding the incidence of death or AMI [49]. 
However, even though these 4 studies suggest that CABG is 
the best revascularization strategy for diabetics, they were 
not designed to evaluate specific revascularization strategies 
in this patient group, and therefore did not have enough sta-
tistical power to draw definitive conclusions about that issue. 
  Recently, the CARDia (Coronary Artery Revasculariza-
tion in Diabetes) study tried to address the efficacy and 
safety of PCI compared to CABG in diabetics with sympto-
matic, multivessel or complex single-vessel CAD [50]. Pa-
tients were followed for a median of 1 year; 65% of those 
undergoing PCI had 3-vessel CAD, and of these, 88% had 
complete myocardial revascularization, with pharmacologic 
stents in 69% of cases and a mean of 3.6 stents per patient. In 
the CABG group, 60% had 3-vessel CAD, 90% of whom had 
complete myocardial revascularization, with 94% with inter-
nal mammary grafts to the LAD artery and a mean of 2.9 
grafts per patient. The primary endpoint of the study was the 
combination of death, nonfatal AMI or CVA, and the secon-
dary endpoint included repeat revascularization. At 1 year, 
no statistically significant difference was found between 
treatment strategies regarding the primary endpoint, but 
considering the secondary endpoint a significant difference 
in favor of CABG was found, due to increased repeat revas-
cularization procedures in the PCI group. Nonetheless, the 
short follow-up and small patients number somewhat limit 
the study´s conclusions.  
  Therefore, it is clear that with all amount of information 
we have, and before the results of the FREEDOM study [51] 
are available, clinical judgment may be the best way to de-
cide about the best revascularization strategy in diabetics 
with stable CAD and preserved LV function. Pereira et al 
[52] studied  the ability of clinical judgment to predict the 
incidence of cardiovascular end-points in patients with mul-
tivessel CAD [53] and showed that when clinical decision 
pointed against PCI, but due to randomization patients un-
derwent that strategy (discordant status), these patients had 
more composite endpoints than those in the concordant Choosing a Revascularization Strategy in Patients with Diabetes  Current Cardiology Reviews, 2010, Vol. 6, No. 4    335 
 
status. As the authors pointed out, it seemed that physicians 
could identify patients who would be suited or not to PCI.  
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